Exhibit 3 details the pathway from discovery to treatment, including venture funding, clinical research, deals, and patient outcomes. See the evolution of cell and gene therapies: bit.ly/4aTHilK. #celltherapy #genetherapy

The findings of a 2-MIXIP study can help manage cancer patients' symptoms more effectively and enhance clinical decision-making. #oncology

bit.ly/3QxDX43

Between 2017 and 2022, the average annual economic value of drugs legally purchased through IOPs in the U.S. was $28Bn, with a total aggregate value of $167Bn over six years. Discover the economic impact of IOPs: bit.ly/3U8IWsC.

Patient organizations play a critical role in the U.S., particularly in rare diseases, oncology, childhood diseases, and birth defects. Dive into the comprehensive analysis of their impact: bit.ly/3W54qJN. #PatientOutcomes

Replay the Global Trends in R&D 2024 webinar featuring Tim Opler, Ph.D., Managing Director at Torreya, as he discusses the impact of AI. Learn how it’s revolutionizing and augmenting clinical development: bit.ly/446V6Xx. #RandD #AI

The new 18-gene prostate cancer test may reduce more burdensome additional testing while maintaining highly sensitive detection of high-grade cancer in patients undergoing PSA screening. #Oncology

bit.ly/3JmI92v

📢 Join us for the 2024 Patient Organization Webinar Series kickoff 4/25. The first webinar features IQVIA Institute’s Executive Director @murray_aitken and Jon Morris of IQVIA.

Patient organization leaders are encouraged to join: bit.ly/3vVPa7k

Patients' decisions on biosimilar products are heavily influenced by insurance coverage and potential out-of-pocket costs. Gain further insights: bit.ly/3VYOrgd. #Biosimilars #PharmaSpending

🔍 Journey through the Global Use of Medicines 2024 report for historical and projected per capita use of medicine from 2013–2028. There are striking variations, with Japan and Western Europe leading. bit.ly/4aZTbX3 🌍💊

Last week's public working session in Brussels shed light on preparing European infrastructure and healthcare systems for the latest advances in cancer care through radioligand therapy. Dive into the report on Succeeding with Innovation: bit.ly/3Q4iMWI. #CancerResearch

POLL Question: What percentage of the neurology pipeline in 2023 consisted of small molecule products?

A) 88%
B) 72%
C) 95%

Find out the answer in our report: bit.ly/3vX3egM.

#RandD #ClinicalResearch

From 2014 to 2023, innovative approaches such as cell and gene therapies, ADCs, and multi-specific antibodies have skyrocketed to 25% of oncology clinical trials. bit.ly/3Q4JmPA. #ClinicalTrials

Learn why an estimated 100 million doses were missed in 2021-2022 and other key insights in our Trends in Global Adult Vaccination research brief: bit.ly/3xy8asQ. #vaccines #COVID19

The arrival of new immunology biosimilars is set to intensify competition in a rapidly expanding sector. Review historical and projected volume trends in our report: bit.ly/49EXw0V. #Biosimilars

A study by JAMA Oncology investigates whether neighborhood socioeconomic deprivation is associated with symptom burden, psychological distress, and quality-of-life (QOL) among head and neck cancer (HNC) survivors. #Oncology

bit.ly/3VXvEBN

Managing Director at Torreya, Tim Opler, Ph.D., discusses the explosive growth in obesity clinical trials, paralleling the rise of immuno-oncology in 2014-2015. Watch the Global Trends in R&D 2024 webinar for more trends: event.on24.com/wcc/r/4534072/… #ClinicalTrials #Obesity

On average, biosimilars see a 50% drop in sales prices within the initial 12 quarters post-launch in diverse markets. Download the full report on Long-term Market Sustainability for Infused Biosimilars in the U.S.: bit.ly/4d1xxDC. #Biosimilars

In 2021, European markets saw a significant rise in biosimilar medicines, reaching €9.7Bn and accounting for 37% of total biologics in treatment days. Explore further insights in our report on Unlocking Biosimilar Potential: bit.ly/4d1poPN. #Biosimilars 💊📈

Memory-related impairments in type 2 diabetes may be mediated by insulin resistance and hyperglycemia. #Diabetes #ClinicalResearch

bit.ly/3VV9WP3

The IQVIA Institute report on Trends in Adult Vaccinations in the U.S. 2024 reveals new insights. Reimbursement amounts for pharmacies vary across states, from covering costs to around $25. bit.ly/3UiX9EI #Vaccinations